Moores Members Recognized as UC San Diego Ranked 9th in World for Most Influential Researchers
|
UC San Diego continues to lead global research with 56 recognitions on the 2024 Highly Cited Researchers list compiled by Clarivate—25 of these are for Moores Members, which underscores the importance of multidisciplinary research across a range of fields. Learn More>>
|
Patient Grateful for Life-Saving Lung Cancer Treatment
|
Moores Member and thoracic surgeon Mark Onaitis, MD delivered life-saving care to lung cancer patient David Katz, who expresses his gratitude. Learn More>>
|
Moores Member Leads Study on How Artificial Intelligence Could Automate Genomics Research
|
A study led by Moores Member Trey Ideker, PhD demonstrates how large language models can accelerate functional genomics research by uncovering gene functions and interactions to generate testable hypotheses more rapidly. Learn More>>
|
American Society of Hematology (ASH) Mixer in San Diego
|
Attend the ASH Reception at City Sights—the rooftop venue at the Marriott Gaslamp Quarter, Altitude Sky Lounge—on Saturday, December 7, 2024 at 7:30 p.m. to connect with ASH attendees, colleagues, and community hem-onc partners, while enjoying views, beverages, and appetizers. RSVP Now>>
|
|
|
| PD-1 and CD73 on naive CD4+ T cells synergistically limit responses to self
|
Alessandro D. Sette, PhD (Hematologic Malignancies)
|
|
|
|
Full-length direct RNA sequencing reveals extensive remodeling of RNA expression, processing and modification in aging Caenorhabditis elegans
|
Amy E. Pasquinelli, PhD (Cancer Biology and Signaling)
|
|
|
| Multifaceted cancer alleviation by cowpea mosaic virus in a bioprinted ovarian cancer peritoneal spheroid model
|
Nicole F. Steinmetz, PhD (Solid Tumor Therapeutics)
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
LOI Deadline: January 5, 2025
Application Deadline: February 5, 2025
Budget: Not limited for 5 years
|
LOI Deadline: January 16, 2025
Application Deadline: February 16, 2025
Budget: $275,000 for 2 years
|
|
|
CLINICAL TRIALS OFFICE (CTO)
|
68284528MMY2003: A Phase II, Multicohort Open-Label Study of JNJ68284528, a Chimeric Antigen Receptor T Cell (CART) Therapy Directed Against BCMA in Subjects with Multiple Myeloma
PI: Caitlin Costello, MD
NCT: NCT04133636
D419ML00003: A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)
PI: Lyudmila Bazhenova, MD
NCT: NCT06008093
|
|
|
|
